The antibodies used were as follows: Alexa Fluor® 488-conjugated anti-human natural killer group 2 membrane C (NKG2C) from R&D Systems (Minneapolis, MN, USA) and anti-human CD159a (NKG2A)-PE and anti-human NKp80-PE (Beckman Coulter, Miami, FL, USA). The following antibodies against human antigens were from BioLegend: fluorescein isothiocyanate (FITC)-conjugated anti-CD8a, anti-CD16, anti-CD158a/h, and anti-CD158e1; phycoerythrin (PE)-conjugated anti-CD56, anti-NKp30, anti-NKp44, anti-NKp46, anti-CD57, anti-NKG2D, anti-CD158b, and anti-CD158f; PE-Cy7-conjugated anti-CD3 and anti-CD56; APC-conjugated anti-CD16 and anti-CD94 monoclonal antibodies; and APC-Cy7-conjugated anti-CD45. The APC conjugated anti-mouse CD45 antibody was from BioLegend.
The absolute number of cells was calculated using fluorescent beads (Flow-Count; Beckman Coulter, Brea, CA, USA) according to the manufacturer’s instructions.